Homocysteine: a newly recognized risk factor for osteoporosis?
Increased plasma homocysteine has been suggested to be an independent risk factor for osteoporotic fractures in elderly persons. Little is known, however, about the mechanistic role of Hcy in osteoporosis, while epidemiological evidence is further reinforced by genetic studies that show an association between the common MTHFR polymorphism and the risk of osteoporosis.
The regulation of Hcy overproduction and the modulation of the inflammatory substrate could represent additional therapeutic approaches for osteoporosis prevention as well as for cardiovascular protection.
Quatrefolic helps in hot flashes
Hormone replacement therapy (HRT) is the first treatment option in hot flashes. Estrogens stimulate the production of serotonin and endorphins: after menopause, there is a 50% decrease in levels of serotonin corresponding to declining estrogen levels. Nevertheless, recently serious risk of hormone therapy has been recognized with prompting researchers to seek new alternatives.
Folate supplementation, like Quatrefolic®, is today recommended as an affordable and accessible method. Studies have shown that folate* supplementation significantly ameliorates hot flashes in postmenopausal women, with a mechanism similar to HRT, by interacting with monoamine neurotransmitters in the brain. The 5-Methyltetrahydrofolate (Methylfolate or 5-MTHF), the metabolically active and tissue-usable form of folic acid is essential for the biosynthesis of the monoamine neurotransmitters serotonin and noradrenaline, and in hot flashes, it lowers noradrenaline and increases serotonin activities.
Vitaminic supplementation, as Quatrefolic®, is a well-known option for all women, helpful not only for hot flashes but for general women’s health.
* in the form of folic acid